Somnigroup International (NYSE:SGI) reached an agreement to acquire Leggett & Platt (NYSE:LEG) in an all-stock transaction valued at approximately $2.5 billion, a move that unites the world's largest ...

Prime Minister Anthony Albanese has ruled out means-testing the National Disability Insurance Scheme, reaffirming the programme's commitment to universality despite its ballooning $55.1 billion price ...

The a2 Milk Company (ASX:A2M) has reported a mismatch between surging consumer demand and supply chain capacity for its infant milk formula business in China. According to a trading update released ...

Logistics giant Brambles (ASX:BXB) is bracing for a potential compensation bill exceeding $100 million following a landmark Federal Court ruling that found the company misled investors over its ...

For years, the global defence industry existed in a sort of polite exile.  In the era of ESG mandates and the "peace dividend ...

Amgen (NASDAQ:AMGN) has announced positive topline results from its Phase 3 clinical trial evaluating a subcutaneous formulation of TEPEZZA (teprotumumab-trbw) for adults with moderate-to-severe ...

The Australian Competition and Consumer Commission has issued a directive to the nation’s financial institutions, demanding an urgent overhaul of due diligence processes following a massive mortgage ...

Medicus Pharma (NASDAQ:MDCX) has reached a critical regulatory milestone, submitting an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration (FDA) for its lead candidate, ...

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug ...

Mayne Pharma Group (ASX:MYX) has escalated its legal dispute with Cosette Pharmaceuticals, filing a substantial damages claim in the Supreme Court of New South Wales. The lawsuit follows the December ...

Inghams Group (ASX:ING) reported a challenging first half for the 2026 fiscal year, with underlying earnings falling significantly as the company navigates a complex operational "reset." For H1 FY26, ...

Mesoblast shares were in focus Monday after the company announced positive formal feedback from the U.S. Food and Drug Administration (FDA) regarding its allogeneic cell therapy, rexlemestrocel-L. The ...